DTN 164: The AI Era Is Creating a Bug-Hunting Arms Race

Plus: Blue Origin's mega-rocket explodes, race to mine the deep sea, IBM's first pure-play quantum chip foundry, NASA selects companies for moon base awards, and more.

DTN 163: The race to develop American-made nuclear fuel

Plus: Biomanufacturing to reshape organ transplants, grid batteries are booming, quantum's make-or-break moment, growing chickens in 3D printed eggs, Japan sells out of robot wolves, in-space refueling demo, and more.

DTN 162: Implantable living materials deliver drugs on demand

Plus: Helium-3 lunar gold rush, Virgin Galactic to begin commercial service, Cowboy files for 20k orbital data centers, non-viral gene therapy, real life gundams, and more.

DTN 161: The Great US Missile Shortage

Plus: China opens rocket launches to international satellites, the future of IVF, a geothermal IPO, big tech targets drug discovery, DARPA eyes commercial space boom, and more.

DTN 160: Fusion Company Applies to Join US Power Grid

Plus: Pentagon's drone spending spree, air taxis come to NYC, Zuck's virtual biology initiative, DeepSeek's new model, FDA wants to accelerate clinical trails with AI, and more.

DTN 159: Neo-primes are changing how America wages war

Plus: New Glenn suffers upper stage malfunction, China ramps up satellite capacity, cracks in fusion's funding boom, robot marathon, slime-like artificial muscles, cocaine-fueled salmon, and more.

Applied Deep Tech and the European Founder Revolution with NP-Hard Ventures' Paul Veugen

Paul Veugen is co-founder and partner at NP-Hard Ventures, an Amsterdam-based early-stage venture capital firm investing in pre-seed and seed companies solving the hardest problems across robotics, defense tech, and foundational infrastructure.

DTN 158: Will synthetic mirror life kill us all?

Plus: nuclear reactors on the moon, implantable pharmacies, 3D printing batteries, first complete human genome loaded onto quantum computer, Science Corp gets ready for brain implant, ARPA-E doubles down on fusion, and more.

Investing at the Frontier of AI and Biology with Amino Collective's Nirmesh Patel

Nirmesh Patel is an investor at Amino Collective, an early-stage health and bio fund investing at the intersection of AI and the life sciences.

DTN 157: The Era of Quantum Computers is Nigh

Plus: New frontiers for neural data, the race to land rovers on the moon, Antares receives DOE approval for demo reactor, General Atomics pauses drone wingman flight tests, and more.

Cracking Ammonia's Century-Old Cost Problem with Ammobia's Karen Baert

Karen Baert is co-founder and CEO of Ammobia, a climate tech startup developing a lower-cost, lower-pressure process for clean ammonia production.

DTN 156: We're going back to the f*cking moon

Plus: Navy's big bet on automated submarine production, Texas' $350M nuclear fund, demoing underground wireless communication, the gig workers training humanoid robots, and more.